Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.29
AMRI's Cash to Debt is ranked lower than
51% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. AMRI: 0.29 )
AMRI' s 10-Year Cash to Debt Range
Min: 0.27   Max: 1216.19
Current: 0.29

0.27
1216.19
Equity to Asset 0.47
AMRI's Equity to Asset is ranked higher than
60% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AMRI: 0.47 )
AMRI' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.96
Current: 0.47

0.32
0.96
Interest Coverage 0.52
AMRI's Interest Coverage is ranked lower than
57% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMRI: 0.52 )
AMRI' s 10-Year Interest Coverage Range
Min: 0.52   Max: 1157.93
Current: 0.52

0.52
1157.93
F-Score: 3
Z-Score: 2.43
M-Score: -1.02
WACC vs ROIC
10.33%
77.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 2.07
AMRI's Operating margin (%) is ranked higher than
84% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. AMRI: 2.07 )
AMRI' s 10-Year Operating margin (%) Range
Min: -36.35   Max: 46.92
Current: 2.07

-36.35
46.92
Net-margin (%) -1.19
AMRI's Net-margin (%) is ranked higher than
82% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. AMRI: -1.19 )
AMRI' s 10-Year Net-margin (%) Range
Min: -31.74   Max: 77.21
Current: -1.19

-31.74
77.21
ROE (%) -1.33
AMRI's ROE (%) is ranked higher than
84% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. AMRI: -1.33 )
AMRI' s 10-Year ROE (%) Range
Min: -22.52   Max: 29.93
Current: -1.33

-22.52
29.93
ROA (%) -0.65
AMRI's ROA (%) is ranked higher than
85% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. AMRI: -0.65 )
AMRI' s 10-Year ROA (%) Range
Min: -17.99   Max: 23.57
Current: -0.65

-17.99
23.57
ROC (Joel Greenblatt) (%) 2.57
AMRI's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. AMRI: 2.57 )
AMRI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -35.27   Max: 98.65
Current: 2.57

-35.27
98.65
Revenue Growth (3Y)(%) 8.20
AMRI's Revenue Growth (3Y)(%) is ranked higher than
80% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. AMRI: 8.20 )
AMRI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.5   Max: 78.2
Current: 8.2

-1.5
78.2
EPS Growth (3Y)(%) -54.80
AMRI's EPS Growth (3Y)(%) is ranked higher than
53% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. AMRI: -54.80 )
AMRI' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.1   Max: 37.3
Current: -54.8

-58.1
37.3
» AMRI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

AMRI Guru Trades in Q1 2014

Steven Cohen 25,400 sh (New)
George Soros 48,700 sh (New)
Jim Simons 696,690 sh (+35.91%)
Murray Stahl 56,000 sh (unchged)
Chuck Royce 1,344,610 sh (-4.81%)
Joel Greenblatt 197,771 sh (-13.80%)
» More
Q2 2014

AMRI Guru Trades in Q2 2014

Murray Stahl 56,000 sh (unchged)
George Soros Sold Out
Chuck Royce 1,315,610 sh (-2.16%)
Jim Simons 579,842 sh (-16.77%)
Joel Greenblatt 102,934 sh (-47.95%)
» More
Q3 2014

AMRI Guru Trades in Q3 2014

Paul Tudor Jones 16,255 sh (New)
Murray Stahl 56,000 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce 1,142,670 sh (-13.15%)
Jim Simons 209,242 sh (-63.91%)
» More
Q4 2014

AMRI Guru Trades in Q4 2014

Paul Tudor Jones 24,200 sh (+48.88%)
Chuck Royce 1,236,016 sh (+8.17%)
Murray Stahl 56,000 sh (unchged)
Jim Simons 126,142 sh (-39.71%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 19.08
AMRI's Forward P/E is ranked higher than
92% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMRI: 19.08 )
N/A
P/B 2.60
AMRI's P/B is ranked higher than
86% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. AMRI: 2.60 )
AMRI' s 10-Year P/B Range
Min: 0.28   Max: 3.08
Current: 2.6

0.28
3.08
P/S 2.17
AMRI's P/S is ranked higher than
94% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. AMRI: 2.17 )
AMRI' s 10-Year P/S Range
Min: 0.31   Max: 2.93
Current: 2.17

0.31
2.93
POCF 312.67
AMRI's POCF is ranked higher than
88% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMRI: 312.67 )
AMRI' s 10-Year POCF Range
Min: 4.9   Max: 314.17
Current: 312.67

4.9
314.17
EV-to-EBIT 127.10
AMRI's EV-to-EBIT is ranked higher than
90% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMRI: 127.10 )
AMRI' s 10-Year EV-to-EBIT Range
Min: -448.8   Max: 333.6
Current: 127.1

-448.8
333.6
Current Ratio 3.92
AMRI's Current Ratio is ranked higher than
71% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. AMRI: 3.92 )
AMRI' s 10-Year Current Ratio Range
Min: 2.43   Max: 17.42
Current: 3.92

2.43
17.42
Quick Ratio 2.90
AMRI's Quick Ratio is ranked higher than
66% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. AMRI: 2.90 )
AMRI' s 10-Year Quick Ratio Range
Min: 1.96   Max: 17.25
Current: 2.9

1.96
17.25
Days Inventory 75.88
AMRI's Days Inventory is ranked higher than
91% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMRI: 75.88 )
AMRI' s 10-Year Days Inventory Range
Min: 21.14   Max: 125.59
Current: 75.88

21.14
125.59
Days Sales Outstanding 94.55
AMRI's Days Sales Outstanding is ranked higher than
76% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. AMRI: 94.55 )
AMRI' s 10-Year Days Sales Outstanding Range
Min: 30.71   Max: 169.08
Current: 94.55

30.71
169.08

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.20
AMRI's Price/Tangible Book is ranked higher than
79% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. AMRI: 4.20 )
AMRI' s 10-Year Price/Tangible Book Range
Min: 0.39   Max: 16.72
Current: 4.2

0.39
16.72
Price/DCF (Projected) 3.10
AMRI's Price/DCF (Projected) is ranked higher than
96% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMRI: 3.10 )
AMRI' s 10-Year Price/DCF (Projected) Range
Min: 0.49   Max: 2.61
Current: 3.1

0.49
2.61
Price/Median PS Value 1.30
AMRI's Price/Median PS Value is ranked higher than
80% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. AMRI: 1.30 )
AMRI' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 15.07
Current: 1.3

0.25
15.07
Price/Peter Lynch Fair Value 7.40
AMRI's Price/Peter Lynch Fair Value is ranked higher than
96% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMRI: 7.40 )
AMRI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.93   Max: 6.29
Current: 7.4

0.93
6.29
Earnings Yield (Greenblatt) 0.80
AMRI's Earnings Yield (Greenblatt) is ranked higher than
86% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. AMRI: 0.80 )
AMRI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 15.1
Current: 0.8

0.3
15.1
Forward Rate of Return (Yacktman) 16.33
AMRI's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 167 Companies
in the Global Biotechnology industry.

( Industry Median: 15.43 vs. AMRI: 16.33 )
AMRI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -17.6   Max: 23.6
Current: 16.33

-17.6
23.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AYM.Germany,
Albany Molecular Research Inc is a Delaware corporation incorporated on June 20, 1991. It is a contract research and manufacturing organization providing customers integrated drug discovery, development and manufacturing services. The Company provides services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of Active Pharmaceutical Ingredients (API) and drug product for existing and experimental new drugs, as well as research, development and manufacturing for the agrochemical and other industries. With locations in the United States, Europe, and Asia, it maintains geographic proximity and flexible cost models. The Company has organized its activities into two distinct segments: Large Scale Manufacturing (LSM) and Discovery, Drug Development and Small-Scale Manufacturing (DDS). Its LSM activities include pilot- to commercial-scale production of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling, and high potency and controlled substance manufacturing. Its remaining activities, including drug lead discovery, in vitro biology and DMPK, lead optimization, drug development, and small-scale commercial manufacturing, represent its DDS business segment. Its Drug Discovery Services includes assay development and design, screening, natural product services, custom synthesis and library synthesis, medicinal chemistry, bioanalytical services, among others. Its customers include pharmaceutical companies and biotechnology companies, as well as government research entities and non-profit organizations, which are a growing segment of its customer base. It also sells to a more limited extent, to companies who are in the businesses of agriculture, fine chemicals, contract chemical manufacturing, medical devices, and flavoring and cosmetics. The Company competes with contract research companies, contract drug manufacturing companies, research and academic institutions and with the internal research departments of biotechnology companies. The manufacture, transportation and storage of its products are subject to certain international, Federal, state and local laws and regulations.
» More Articles for AMRI

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: TSON, PRTS, FXCM, AMRI, MN Dec 05 2011 
View on AMRI Jun 27 2010 
AMRI Announces Second Quarter 2009 Results Aug 04 2009 
AMRI Announces Fourth Quarter 2008 Results Feb 09 2009 
AMRI Names Senior Director, Analytical and Quality Services Jan 12 2009 

More From Other Websites
5 Stocks Ready for Breakouts Apr 24 2015
AMRI to Announce First Quarter 2015 Results Apr 21 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Apr 07 2015
AMRI to Close Holywell, U.K. API Manufacturing Facility Apr 02 2015
ALBANY MOLECULAR RESEARCH INC Financials Mar 21 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 10-K, Annual Report Mar 16 2015
AMRI to Present at Barclays Global Healthcare Conference Feb 25 2015
AMRI to Present at Barclays Global Healthcare Conference Feb 25 2015
Stocks From Leading Industries Feb 21 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets Feb 17 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 13 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 12 2015
Albany Molecular Research posts 4Q loss Feb 12 2015
Albany Molecular Research posts 4Q loss Feb 12 2015
AMRI Announces Fourth Quarter and Full Year 2014 Results Feb 12 2015
Q4 2014 Albany Molecular Research Inc Earnings Release - Before Market Open Feb 12 2015
AMRI to Announce Fourth Quarter and Full Year Results Jan 29 2015
Drug developer receives $37 million federal research contract Jan 20 2015
AMRI Receives NIH Contract Award for the Formulation Development and Manufacture of Pre-Clinical and... Jan 19 2015
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jan 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK